Trials / Completed
CompletedNCT03728556
A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial of CS1001 as Consolidation Treatment in Subjects With Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer That Has Not Progressed After Prior Concurrent/Sequential Chemoradiotherapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 381 (actual)
- Sponsor
- CStone Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of CS1001 in subjects with locally advanced/unresectable (Stage III) non-small cell lung cancer that has not progressed after prior concurrent/sequential chemoradiotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CS1001 monoclonal antibody | Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months |
| BIOLOGICAL | CS1001 placebo | Participant will receive CS1001 placebo by intravenous infusion every 3 weeks, for up to 24 months |
Timeline
- Start date
- 2018-10-26
- Primary completion
- 2023-04-03
- Completion
- 2023-04-03
- First posted
- 2018-11-02
- Last updated
- 2023-06-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03728556. Inclusion in this directory is not an endorsement.